ZZZhi-Min Zhang

Zhi-Min Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhi-Min Zhang has a total of 363 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Discovery of Arginine-Reactive Covalent Kinase Inhibitors Overcoming Clinical Drug Resistance

    by Zuqin Wang, Xuan Wang, Hong Zhang, Jiahuan He, Lu Wang, Li Ling, Peng Chen, Jibo Kang, Xiaojuan Song, Zhengchao Tu, et al.

    Covalent kinase inhibitors (CKIs) serve as potent therapeutics, yet their development largely depends on conserved cysteine residues. Many kinases lack accessible cysteines or develop resistance mutations at these sites, limiting clinical utility. To diversify targetable nucleophilic amino acids, we developed a modular strategy for arginine reactive CKIs using two warhead types: O-cyanobenzaldehyde (CNBA) and phenylglyoxal (PGO). We first synthesized RA2, a CNBA-based AURKA inhibitor targeting arginine (R220), which showed weak cellular activity (GI50 > 2 μM). Using PGO warhead, we generated covalent inhibitors C1 against ALK-G1202R and L1a against TRKA-G595R; both strongly inhibited arginine-mutant kinases but showed unsatisfactory cellular potency. Further optimization of PGO electrophilicity via methoxy substitution yielded L1c, which exhibited potent cellular activity (GI50 = 0.39 μM) against drug-resistant Ba/F3-CD74-TRKA-G595R cells and sustained target engagement. Collectively, this work expands the CKI toolbox to include arginine-targeting warheads and provides a modular framework to overcome point mutation-driven resistance.

  • Dual‐Site Covalent Targeting Enables BD2‐Selective BET Inhibition With Potent Antitumor Activity in Mice

    by Jibo Kang, Xuan Wang, Hong Zhang, Jieying Lin, Peng Chen, Zuqin Wang, Zengjun Hao, Fengfei Miao, Fengcai Zhang, Tao Li, et al.

    Bromodomain and extra‐terminal (BET) proteins are validated therapeutic targets for cancer, but clinical translation of pan‐BET inhibitors is limited by dose‐limiting toxicities from non‐selective inhibition of BD1/BD2 domains. Herein, we report the first‐ever domain‐selective covalent inhibitor, named i p AE1 , of BET BD2 domains by installing an epoxide warhead onto the scaffold of ABBV‐744. i p AE1 was shown to irreversibly modify Glu438 and His437 (to a lesser extent) located within the BRD4(2) binding pocket via a dual‐covalent mechanism, as evidenced by its chemical probe p AE1 . Furthermore, i p AE1 exhibited exceptional potency against BRD4(2) ( K d = 0.096 nM) with > 1900‐fold selectivity over BRD4(1), leading to potent and sustained antiproliferative activity in MV4‐11 cells (GI 50 = 1.5 nM). Subsequent live‐cell proteome‐wide profiling validated BRD4 as the primary cellular target of i p AE1 . Consistent with cellular activities, i p AE1 possessed a significantly enhanced antitumor efficacy in an MV4‐11 xenografted mouse model compared to ABBV‐744, presumably due to its on‐target covalent engagement in vivo. Our study thus establishes for the first time a novel targeted covalent inhibition (TCI) strategy that engages two weakly nucleophilic residues within a single bromodomain, an approach generalizable to other compounds targeting E/H, providing a highly selective platform for future development of next‐generation BET inhibitors.

  • Dual‐Site Covalent Targeting Enables BD2‐Selective BET Inhibition With Potent Antitumor Activity in Mice

    by Jibo Kang, Xuan Wang, Hong Zhang, Jieying Lin, Peng Chen, Zuqin Wang, Zengjun Hao, Fengfei Miao, Fengcai Zhang, Tao Li, et al.

    Bromodomain and extra‐terminal (BET) proteins are validated therapeutic targets for cancer, but clinical translation of pan‐BET inhibitors is limited by dose‐limiting toxicities from non‐selective inhibition of BD1/BD2 domains. Herein, we report the first‐ever domain‐selective covalent inhibitor, named i p AE1 , of BET BD2 domains by installing an epoxide warhead onto the scaffold of ABBV‐744. i p AE1 was shown to irreversibly modify Glu438 and His437 (to a lesser extent) located within the BRD4(2) binding pocket via a dual‐covalent mechanism, as evidenced by its chemical probe p AE1 . Furthermore, i p AE1 exhibited exceptional potency against BRD4(2) ( K d = 0.096 nM) with > 1900‐fold selectivity over BRD4(1), leading to potent and sustained antiproliferative activity in MV4‐11 cells (GI 50 = 1.5 nM). Subsequent live‐cell proteome‐wide profiling validated BRD4 as the primary cellular target of i p AE1 . Consistent with cellular activities, i p AE1 possessed a significantly enhanced antitumor efficacy in an MV4‐11 xenografted mouse model compared to ABBV‐744, presumably due to its on‐target covalent engagement in vivo. Our study thus establishes for the first time a novel targeted covalent inhibition (TCI) strategy that engages two weakly nucleophilic residues within a single bromodomain, an approach generalizable to other compounds targeting E/H, providing a highly selective platform for future development of next‐generation BET inhibitors.

  • Open Access

    A New Recruitable E3 Ligase UHRF1 Supporting Targeted Protein Degradation: A Minimal Azide as a Recruitment Ligand

    by Zehong Lin, Kang Duan, Rui Wan, Tao Jiang, Jinzhe Wei, Miao Sun, Mariia A. Skryl'NIkova, Maxim A. Gureev, Zhi‐Min Zhang, Zhang Zhang, et al.

    Targeted protein degradation represents a promising therapeutic strategy, yet its broader application is often limited by the scarcity of usable E3 ligases. Glutathione peroxidase 4 (GPX4) is a key target for inducing ferroptosis, but achieving sustained and potent inhibition remains challenging with conventional enzymatic inhibitors. Herein, we report the first small‐molecule GPX4 degraders that incorporate either electrophilic warheads or a minimal azide group as an E3 recruitment ligand. The azide‐based degrader DK‐5070 effectively drives potent GPX4 degradation, achieving a DC 50 of 17.4 nM and a Dmax of 84%, thereby outperforming larger PROTAC‐based degraders. Notably, DK‑5070 exhibits potent antitumor activity both in vitro (IC 50 = 47.21 nM) and in vivo (TGI = 41.8%), demonstrating significant efficacy as a GPX4 degrader. Mechanistic studies reveal that degradation is mediated through recruitment of the oncogenic E3 ligase UHRF1, which is frequently overexpressed in tumors, underscoring the potential for tumor‐specific protein degradation. This demonstrated small‐molecule degraders that recruit UHRF1 to facilitate targeted degradation of GPX4. In this system, the azide group functions as a minimal recruitment ligand, thereby expanding the E3 ligase toolbox and offering a promising strategy for targeted cancer therapy.

  • Radical Mechanism and Stereochemical Control in Consecutive C–C Bond Formation by the Nonheme Iron Enzyme Hvm1

    by Shengbin Zhou, Jiapeng Zhang, Jia-Yu Zuo, Jianchang Yu, Yi-Fan Du, Rui Wang, Chengkai Wu, Ganlu Zhang, Aolong Shang, Peihong Zhou, et al.

    Iron(II)/2-oxoglutarate-dependent (Fe/2OG) enzymes catalyze consecutive C–C bond formations to assemble complex heterobicyclic ring systems and generate three new stereocenters in piperazine alkaloids helvamide B and the arizonamides through C(sp3)–H activation─a transformation that remains challenging in synthetic chemistry. Here, we report a comprehensive mechanistic study of this unique transformation catalyzed by the Fe/2OG enzyme Hvm1, using a combination of deuterated substrates, substrate analogs bearing electron-withdrawing substituents, and multiple spectroscopic methods (LC-MS, X-ray crystallography, CD spectroscopy, and NMR). The reaction proceeds via consecutive radicaloid C–C (C3′–C2 and C3–C3″) couplings, involving sequential radical attack on the olefin and benzoyl group (Minisci variant), initiated by a C3′ radical generated through C3′ pro-S hydrogen atom transfer (HAT). The first C–C bond (C3′–C2) is formed on the Si-face of C2 with retention of C3′ configuration. The second C–C bond (C3–C3″) formation can proceed with either of two stereochemical senses─antarafacial or suprafacial─relative to the first newly formed C3′–C2 bond: the antarafacial pathway leads to helvamide B, while the suprafacial pathway affords the previously unreported epimer, helvamide A. Crystal structure analysis identifies Y67 as a key residue governing the partitioning of stereochemical outcomes in the second C–C bond formation. Furthermore, the conclusive stereochemical assignment of helvamide B corrects the prior misassignment of the C3′ configuration in the arizonamides.

  • Unique Cysteine-Directed Covalent Inhibition of PRMT1 Suppresses Breast Tumorigenesis

    by Min Shao, Ruining Li, Jinglei Hu, Wenjie Xi, Raghupathi Mutyala, Lulu Guan, Chaoqun Huang, Renhong Sun, Xiaobao Yang, Bo Jin, et al.

    Dysregulation of PRMT1, a key epigenetic enzyme, is strongly implicated in breast cancer pathogenesis. However, developing selective PRMT1 inhibitors has been challenging due to the high conservation of the catalytic domain across PRMT family members. We herein report 17zh (MS3-123), the first small-molecule, nanomolar covalent inhibitor targeting the unique Cys119 within the SAM-binding pocket of PRMT1 (IC50 = 11.4 nM) with over 17-96-fold selectivity against other type I PRMTs subfamily and >439-fold selectivity against type II PRMT5. 17zh selectively engages Cys119, inhibiting PRMT1 activity at both enzymatic and cellular levels. Functionally, 17zh suppressed breast cancer cell proliferation, migration, invasion, induced cell cycle arrest and apoptosis, and impaired tumor growth in vivo in the MDA-MB-231-xenograft model. Our findings establish 17zh as both a valuable chemical probe for PRMT1 research and a promising lead candidate for breast cancer treatment, highlighting the potential of covalent targeting for selective epigenetic drug discovery.

  • Open Access

    Creating highly active fluoroacetate dehalogenases via gate-based synergetic chain design

    by Cui-Zhen Wang, Huisi Huang, Zhihui Hu, Longwei Gao, Zhi-Qiao Lin, Ming Shi, Zhiyong Song, Min Li, Yueming Wang, Ke-Wei Chen, et al.

    Gate residues, acting in concert with distal dynamic networks, are emerging as critical yet underexploited regulators of enzymatic catalysis. Here we show that conformational dynamics analysis of fluoroacetate dehalogenase RPA1163 reveals a gate-based allosteric pair (K181-W185) that governs substrate access and reactivity. Network engineering of this pair yields a double mutant with high turnover number for α-fluorophenylpropionic acid (turnover number > 2 × 10⁵), establishing gate-centric allostery as a generalizable design principle. Structural and molecular dynamics analyses show that the activity enhancement arises from stabilization of catalytically competent open states through long-range coupling. Extension of this strategy to three additional dehalogenases confirms the universality of gate-based dynamic rewiring. Leveraging this framework, we establish a robust biocatalytic platform for stereoselective synthesis of α-fluoro and α-hydroxy carboxylic acids, achieving high productivity (turnover number > 3.7 × 10⁶) and enabling decagram-scale preparation of pharmaceutically relevant intermediates with high yield and enantioselectivity. Together, these findings establish gate-residue allostery as a powerful concept in protein engineering, bridging conformational dynamics with translational biocatalysis.


  • Structure-Based Design of Potent and Highly Selective NUAK1 Inhibitors by Exploiting a Unique Glutamate Switch for the Prevention of Tumor Growth, Migration, and Invasion

    by Shan Li, Yingao Wang, Xuechen Liu, Hong Zhang, Chong Lei, Zhen Wang, Yuqing Zhang, Xiaoli Du, Lingrui Xu, Ziwen Li, et al.

    NUAK1, an AMPK-related kinase overexpressed in cancers, plays a crucial role in tumor metastasis and cell survival, making it an attractive cancer therapeutic target. Herein, we report potent, selective NUAK1 inhibitors via structure-guided repurposing of a covalent JAK3 inhibitor. By capitalizing on the critical structural difference─Cys909 in JAK3 versus Glu139 in NUAK1─we substituted the electrophilic warhead with glutamate-favoring moieties, a modification that confers selective NUAK1 targeting. Supporting this design rationale, cocrystal structures verify the specific engagement of these moieties with the Glu139 residue of NUAK1. Among the synthesized analogs, candidate compound 10i exhibits subnanomolar NUAK1 inhibition (IC50 = 0.49 nM) and kinome-wide selectivity. Besides, 10i suppresses proliferation, migration, and invasion of triple-negative breast cancer cells, reverses EMT markers, and shows robust antitumor efficacy in mouse xenografts. This study provides a promising lead and validates Glu139 as an anchor for selective NUAK1 targeting.


  • Open Access

    Tuning aromatic cage occupancy in prenyltransferases enables selective and efficient production of rare c-prenylated flavonoids

    by Ruiying Qiu, Huisi Huang, Junxi Chi, Longwei Gao, Qilin Gao, Min Li, Menghao Cai, Haishuang Yu, Shijie Wang, Zhilan Qian, et al.

    C-prenylated flavonoids possess notable pharmaceutical potential, but their production is hindered by the challenging selective prenylation of their unstable polyphenolic cores. Natural prenyltransferases offer a direct route but suffer from low activity and incomplete mechanistic understanding. Here, we report a directed evolution strategy to reshape the active pocket of the prenyltransferase AtaPT, uncovering an aromatic cage that governs both regioselectivity and donor specificity. By tuning cage occupancy, we engineer three mutants with high chemo- and regioselectivity toward dimethylallyl diphosphate or geranyl pyrophosphate. Structural analysis and molecular simulations validate the role of the cage in guiding flavonoid prenylation. Notably, the aromatic cage mechanism observed in AtaPT is not unique and can be recapitulated in homologous enzymes. Introduction of the aromatic cage consistently enhances both activity and selectivity, confirming its crucial role. AtaPT mutants enable the efficient and scalable synthesis of 27 C-prenylated flavonoids, including 8 previously unreported compounds. With an integrated donor regeneration system, preparative-scale biotransformations achieve product titers up to 400 mg/L. This study establishes a selective and scalable biocatalytic platform for flavonoid prenylation and offers mechanistic insights for enzyme engineering.


  • Open Access

    Discovery of SKP2‐Recruiting PROTACs for Target Protein Degradation

    by Guanjun Dong, Aima Huang, Ziqing Zhao, Bikai Lai, Xin Pan, Huiyu Yang, Xiaohan Xu, Tianwei Wang, Fangchen Zhao, Zhimin Zhang, et al.

    Proteolysis targeting chimeras (PROTACs) have emerged as an intriguing therapeutic strategy for targeted protein degradation (TPD), functioning as heterobifunctional compounds that induce the redirection of E3 ligases to ubiquitinate neo‐substrates for proteasomal degradation. Despite the presence of over 600 E3 ligases, only a limited subset has been successfully harnessed for TPD. This study demonstrates that S‐phase kinase‐associated protein 2 (SKP2), the substrate receptor of the Cullin RING ligase 1 (CRL1) subfamily, can be employed for TPD using a selective, non‐covalent SKP2 recruiter, SL1 . We designed and synthesized SKP2‐recruiting degraders by linking SL1 to the BRD4 inhibitor JQ1 . These compounds effectively induce BRD4 degradation in MV‐4‐11 cells, with the most potent compound 2‐1 exhibiting a half‐maximal degradation (DC 50 ) of 298 nM, validating their potential as PROTACs. Mechanistic investigations show that 2‐1 promotes BRD4 ubiquitination and subsequent degradation in a proteasome‐ and neddylation‐dependent manner, which can be rescued by SKP2 knockdown and knockout. We further demonstrate that SKP2‐directed PROTACs effectively degrade Androgen receptor (AR) in 22RV1 cells. These findings emphasize that SKP2, frequently overexpressed in various tumor cells, can be successfully exploited for TPD through non‐covalent PROTACs, expanding the pool of E3 ligases available for potential therapeutic applications.